Melatonin modulation of intracellular signaling pathways in hepatocarcinoma HepG2 cell line: Role of the MT1 receptor

Journal of Pineal Research

Volumn 51, Issue 4, 2011, Pages 463-471

  Carbajo Pescador, Sara ^a   García Palomo, Andrés ^b   Martín Renedo, Javier ^a   Piva, Maiara ^a   González Gallego, Javier ^a   Mauriz, José L ^a  

^a UNIVERSITY OF LEÓN   (Spain)

^b Complejo Asistencial Universitario de León   (Spain)

Author keywords

cAMP; hepatocarcinoma; melatonin; mitogen activated protein kinases

Indexed keywords

CYCLIC AMP; LUZINDOLE; MELATONIN; MELATONIN 1 RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CELL STRAIN HEPG2; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; SIGNAL TRANSDUCTION;

BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; CYCLIC AMP; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MELATONIN; MITOGEN-ACTIVATED PROTEIN KINASES; POLYMERASE CHAIN REACTION; RECEPTOR, MELATONIN, MT1; SIGNAL TRANSDUCTION;

EID: 80054818699     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2011.00910.x     Document Type: Article

References (59)

1. Jemal A, Bray F, Center MM, et al., Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Cornella H, Alsinet C, Villanueva A,. Molecular pathogenesis of hepatocellular carcinoma. Alcohol Clin Exp Res 2011; 35: 821-825.
3. Rossi L, Zoratto F, Papa A, et al., Current approach in the treatment of hepatocellular carcinoma. World J Gastrointest Oncol 2010; 2: 348-359.
4. Alves RC, Alves D, Guz B, et al., Advanced hepatocellular carcinoma. Review of targeted molecular drugs. Ann Hepatol 2011; 10: 21-27.
5. Hill SM, Blask DE,. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res 1988; 48: 6121-6126. (Pubitemid 18266811)
6. Papazisis KT, Kouretas D, Geromichalos GD, et al., Effects of melatonin on proliferation of cancer cell lines. J Pineal Res 1998; 25: 211-218. (Pubitemid 29029898)
7. Petranka J, Baldwin W, Biermann J, et al., The oncostatic action of melatonin in an ovarian carcinoma cell line. J Pineal Res 1999; 26: 129-136. (Pubitemid 29183115)
8. Farriol M, Venereo Y, Orta X, et al., In vitro effects of melatonin on cell proliferation in a colon adenocarcinoma line. J Appl Toxicol 2000; 20: 21-24. (Pubitemid 30093182)
9. Otalora BB, Madrid JA, Alvarez N, et al., Effects of exogenous melatonin and circadian synchronization on tumor progression in melanoma-bearing C57BL6 mice. J Pineal Res 2008; 44: 307-315. (Pubitemid 351392944)
10. Shiu SY, Law IC, Lau KW, et al., Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype. J Pineal Res 2003; 35: 177-182. (Pubitemid 37100395)
11. Jung-Hynes B, Reiter RJ, Ahmad NJ,. Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. J Pineal Res 2010; 48: 9-19.
12. Ishii H, Tanaka N, Kobayashi M, et al., Gene structures, biochemical characterization and distribution of rat melatonin receptors. J Physiol Sci 2009; 59: 37-47.
13. Maurice P, Daulat AM, Turecek R, et al., Molecular organization and dynamics of the melatonin MT receptor/RGS20/G(i) protein complex reveal asymmetry of receptor dimers for RGS and G(i) coupling. EMBO J 2010; 29: 3646-3659.
14. Mao L, Cheng Q, Guardiola-Lemaitre B, et al., In vitro and in vivo antitumor activity of melatonin receptor agonists. J Pineal Res 2010; 49: 210-221.
15. Yuan L, Collins AR, Dai J, et al., MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol Cell Endocrinol 2002; 192: 147-156. (Pubitemid 34667233)
16. Shiu SY, Li L, Xu JN, et al., Melatonin-induced inhibition of proliferation and G1/S cell cycle transition delay of human choriocarcinoma JAr cells: possible involvement of MT2 (MEL1B) receptor. J Pineal Res 1999; 27: 183-192. (Pubitemid 29487963)
17. Kobayashi Y, Itoh MT, Kondo H, et al., Melatonin binding sites in estrogen receptor-positive cells derived from human endometrial cancer. J Pineal Res 2003; 35: 71-74. (Pubitemid 36960343)
18. Garcia-Navarro A, Gonzalez-Puga C, Escames G, et al., Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture. J Pineal Res 2007; 43: 195-205. (Pubitemid 47078925)
19. Winczyk K, Fuss-Chmielewska J, Lawnicka H, et al., Luzindole but not 4-phenyl-2- propionamidotetralin (4P-PDOT) diminishes the inhibitory effect of melatonin on murine Colon 38 cancer growth in vitro. Neuro Endocrinol Lett 2009; 30: 657-662.
20. Min L, He B, Hui L,. Mitogen-activated protein kinases in hepatocellular carcinoma development. Semin Cancer Biol 2011; 21: 10-20.
21. Joo SS, Yoo YM,. Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: therapeutic implications for prostate cancer. J Pineal Res 2009; 47: 8-14.
22. Mao L, Yuan L, Slakey LM, et al., Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway. Breast Cancer Res 2010; 12: R107.
23. Cabrera J, Negrin G, Estevez F, et al., Melatonin decreases cell proliferation and induces melanogenesis in human melanoma SK-MEL-1 cells. J Pineal Res 2010; 49: 45-54.
24. Chan AS, Lai FP, Lo RK, et al., Melatonin mt1 and MT2 receptors stimulate c-Jun N-terminal kinase via pertussis toxin-sensitive and -insensitive G proteins. Cell Signal 2002; 14: 249-257. (Pubitemid 34102454)
25. Martin-Renedo J, Mauriz JL, Jorquera F, et al., Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line. J Pineal Res 2008; 45: 532-540.
26. Carbajo-Pescador S, Martin-Renedo J, Garcia-Palomo A, et al., Changes in the expression of melatonin receptors induced by melatonin treatment in hepatocarcinoma HepG2 cells. J Pineal Res 2009; 47: 330-338.
27. Denizot F, Lang R,. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986; 89: 271-277. (Pubitemid 16080782)
28. Fillmann NH, Kretzmann NA, San-Miguel B, et al., Glutamine inhibits over-expression of pro-inflammatory genes and down-regulates the nuclear factor kappaB pathway in an experimental model of colitis in the rat. Toxicology 2007; 236: 217-221.
29. Crespo I, García-Mediavilla MV, Almar M, et al., Differential effects of dietary flavonoids on reactive oxygen and nitrogen species generation and changes in antioxidant enzyme expression induced by proinflammatory cytokines in Chang Liver cells. Food Chem Toxicol 2008; 46: 1555-1569.
30. Vanecek J,. Cellular mechanisms of melatonin action. Physiol Rev 1998; 78: 687-721. (Pubitemid 28340600)
31. Huang P, Han J, Hui L,. MAPK signaling in inflammation-associated cancer development. Protein Cell 2010; 1: 218-226.
32. Jung-Hynes B, Schmit TL, Reagan-Shaw SR, et al., Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model. J Pineal Res 2011; 50: 140-149.
33. Cabrera J, Negrin G, Estevez F, et al., Melatonin decreases cell proliferation and induces melanogenesis in human melanoma SK-MEL-1 cells. J Pineal Res 2010; 49: 45-54.
34. Garcia-Navarro A, Gonzalez-Puga C, Escames G, et al., Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture. J Pineal Res 2007; 43: 195-205. (Pubitemid 47078925)
35. Naji L, Carrillo-Vico A, Guerrero JM, et al., Expression of membrane and nuclear melatonin receptors in mouse peripheral organs. Life Sci 2004; 74: 2227-2236. (Pubitemid 38249544)
36. Ishii H, Tanaka N, Kobayashi M, et al., Gene structures, biochemical characterization and distribution of rat melatonin receptors. J Physiol Sci 2009; 59: 37-47.
37. Dubocovich ML, Markowska M,. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005; 27: 101-110. (Pubitemid 41558442)
38. Hill SM, Frasch T, Xiang S, et al., Molecular mechanisms of melatonin anticancer effects. Integr Cancer Ther 2009; 8: 337-346.
39. Leja-Szpak A, Jaworek J, Pierzchalski P, et al., Melatonin induces pro-apoptotic signaling pathway in human pancreatic carcinoma cells (PANC-1). J Pineal Res 2010; 49: 248-255.
40. Toma CD, Svoboda M, Arrich F, et al., Expression of the melatonin receptor (MT) 1 in benign and malignant human bone tumors. J Pineal Res 2007; 43: 206-213. (Pubitemid 47077224)
41. Schuster C,. Sites and mechanisms of action of melatonin in mammals: the MT1 and MT2 receptors. J Soc Biol 2007; 201: 85-96. (Pubitemid 47360408)
42. Grant SG, Melan MA, Latimer JJ, et al., Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives. Expert Rev Mol Med 2009; 11: e5.
43. Stumpf I, Bazwinsky I, Peschke E,. Modulation of the cGMP signaling pathway by melatonin in pancreatic beta-cells. J Pineal Res 2009; 46: 140-147.
44. Niles LP, Hashemi F,. Picomolar-affinity binding and inhibition of adenylate cyclase activity by melatonin in Syrian hamster hypothalamus. Cell Mol Neurobiol 1990; 10: 553-558.
45. Imbesi M, Uz T, Dzitoyeva S, et al., Melatonin signaling in mouse cerebellar granule cells with variable native MT1 and MT2 melatonin receptors. Brain Res 2008; 1227: 19-25.
46. Browning C, Beresford I, Fraser N, et al., Pharmacological characterization of human recombinant melatonin mt(1) and MT(2) receptors. Br J Pharmacol 2000; 129: 877-886. (Pubitemid 30142898)
47. Nah SS, Won HJ, Park HJ, et al., Melatonin inhibits human fibroblast-like synoviocyte proliferation via extracellular signal-regulated protein kinase/P21(CIP1)/P27(KIP1) pathways. J Pineal Res 2009; 47: 70-74.
48. Joo SS, Yoo YM,. Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: therapeutic implications for prostate cancer. J Pineal Res 2009; 47: 8-14.
49. Esposito E, Genovese T, Caminiti R, et al., Melatonin reduces stress-activated/mitogen-activated protein kinases in spinal cord injury. J Pineal Res 2009; 46: 79-86.
50. Raman M, Chen W, Cobb MH,. Differential regulation and properties of MAPKs. Oncogene 2007; 26: 3100-3112. (Pubitemid 46763006)
51. Bondi CD, Mckeon RM, Bennett JM, et al., MT1 melatonin receptor internalization underlies melatonin-induced morphologic changes in Chinese hamster ovary cells and these processes are dependent on Gi proteins, MEK 1/2 and microtubule modulation. J Pineal Res 2008; 44: 288-298. (Pubitemid 351392943)
52. Qin X, Liu C, Zhou Y, et al., Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk /MAPK signaling pathway. Cell Mol Biol 2010; 56 (Suppl): OL1366-1372.
53. Bacus SS, Gudkov AV, Lowe M, et al., Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 2001; 20: 147-155. (Pubitemid 32150260)
54. Nosjean O, Ferro M, Coge F, et al., Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem 2000; 275: 31311-31317.
55. Pozo D, Garcia-Maurino S, Guerrero JM, et al., mRNA expression of nuclear receptor RZR/RORalpha, melatonin membrane receptor MT, and hydroxindole-O- methyltransferase in different populations of human immune cells. J Pineal Res 2004; 37: 48-54. (Pubitemid 38969020)
56. Lardone PJ, Carrillo-Vico A, Molinero P, et al., A novel interplay between membrane and nuclear melatonin receptors in human lymphocytes: significance in IL-2 production. Cell Mol Life Sci 2009; 66: 516-525.
57. Iskander K, Paquet M, Brayton C, et al., Deficiency of NRH:quinone oxidoreductase 2 increases susceptibility to 7,12-dimethylbenz(a)anthracene and benzo(a)pyrene-induced skin carcinogenesis. Cancer Res 2004; 64: 5925-5928. (Pubitemid 39129385)
58. Hsieh TC, Wang Z, Hamby CV, et al., Inhibition of melanoma cell proliferation by resveratrol is correlated with upregulation of quinone reductase 2 and p53. Biochem Biophys Res Commun 2005; 334: 223-230. (Pubitemid 40978529)
59. Fischer TW, Zmijewski MA, Zbytek B, et al., Oncostatic effects of the indole melatonin and expression of its cytosolic and nuclear receptors in cultured human melanoma cell lines. Int J Oncol 2006; 29: 665-672.